A Phase 1/2 interventional study of HS-410 and Placebo in Bladder Cancer, sponsored by Heat Biologics. Terminated at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-17.
Sponsored by Heat Biologics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms — 3 open to participants now, 8 under way, 4 of them phase 3. BCG Vaccine · Urinary Bladder Neoplasms.
Among the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, this one is the 11th largest by enrollment, is one of 3 that started in 2013, is one of 4 in phase 1/2, and was the 5th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →3 of the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Verity Pharmaceuticals Inc. · Sites in Canada
Ages 18+
Chengdu CoenBiotech Co., Ltd · Sites in China
Ages 18–75
By country, each count listing its studies:
BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 8
First in 1995; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 112 across the 20 interventional studies. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Heat Biologics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Heat Biologics has 1 study filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase I/II study: Phase 1 is an open-label, safety study, patients who previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose intradermal (1*10\^6 cells) HS-410 monotherapy. Phase 2, patients will be randomized to one of three blinded (physician-patient), placebo-controlled groups and receive either intradermal placebo or low dose (1*10\^6 cells) or high dose (1*10\^7 cells) vesigenurtacel-L in combination with induction and maintenance intravesical BCG. Patients who do not receive BCG will be enrolled into an open-label, non-randomized group receiving high dose (1*10\^7 cells) intradermal HS-410 monotherapy.
This study is a two part study: Phase I and Phase II. The Phase 1 portion is an open-label, safety study. Patients will have previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose intradermal (1*10\^6 cells) HS-410 monotherapy. In Phase 2, patients will be assigned to treatment groups based on whether they will receive induction BCG in the typical post-TURBT window. If the investigator plans to administer BCG, patients will be randomized to one of three blinded (physician-patient), placebo-controlled groups and receive either intradermal placebo or low dose (1*10\^6 cells) or high dose (1*10\^7 cells) vesigenurtacel-L in combination with induction and maintenance intravesical BCG. If patients will not receive BCG, they will be enrolled into an open-label, non-randomized group and receive high dose (1*10\^7 cells) intradermal HS-410 monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the open label Phase 1 portion, HS-410 is given as 1\*10\^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
Biological: HS-410
In the Phase 2 portion, HS-410 is given as 1\*10\^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
Biological: HS-410 · Biological: BCG
In the Phase 2 portion, HS-410 is given as 1\*10\^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
Biological: HS-410 · Biological: BCG
In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
Biological: Placebo · Biological: BCG
In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1\*10\^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
Biological: HS-410
Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
Injection containing sterile solution but no cells
Vaccine derived from a live bacterium
Also known as: Bacillus Calmette-Guerin
Phase 1: Safety and Tolerability
To evaluate the safety and tolerability of vesigenurtacel-L
Time frame: Up to 3 years.
Phase 2: 1-year Disease-Free Survival
Arm 1, 2, 3: 1-year DFS in patients with NMIBC treated with BCG in combination with blinded study product (one of two doses of vesigenurtacel-L or placebo) Arm 4: 1-year DFS in patients with NMIBC treat1fv 9 with high dose vesigenurtacel-L monotherapy One-year disease-free survival will be defined as the proportion of patients who are free from recurrent disease, progressive disease, and alive one year after the date of randomization/treatment assignment
Time frame: One year
Proportion of Patients With Recurrence at 3, 6, 12, 18, and 24 Months
Evaluate the proportion of patients with recurrence at 3, 6, 12, 18, and 24 months
Time frame: Up to 2 years
Proportion of Patients With Progressive Disease at 3, 6, 12, 18, and 24 Months
Evaluate the proportion of patients with progressive disease at 3, 6, 12, 18, and 24
Time frame: Up to 2 years
Disease-free Survival at 3, 6, 18, and 24 Months
Evaluate Disease Free Survival at 3, 6, 18 and 24 months
Time frame: Up to 2 years
Overall Disease-free Survival
Evaluate overall Disease Free Survival
Time frame: Up to 3 years
Overall Survival, Expressed as the Number of Participants Alive
Evaluate overall survival (OS)
Time frame: Up to 3 years
Proportion of Patients Undergoing Repeat Transurethral Resection of Bladder Tumor (TURBT) by 12 and 24 Months
Time frame: Up to 2 years
Proportion of Patients Undergoing Cystectomy by 12 and 24 Months
Evaluate the proportion of patients undergoing cystectomy by 12 and 24 months from randomization
Time frame: Up to 2 years
Immunologic Response of PBMCs Via Intracellular Cytokine Staining (ICS) by Flow Cytometry and/or Enzyme-linked Immunosorbent Spot (ELISPOT) on CD8+ Cells After HS-410 Vaccination as Compared to Baseline.
Evaluate the proportion of patients with immunologic response of peripheral blood mononuclear cells (PBMCs) via intracellular cytokine staining (ICS) by flow cytometry and/or ELISPOT on CD8+ cells following vesigenurtacel-L vaccination
Time frame: Up to 2 years
Immunologic Response of Peripheral Blood Mononuclear Cells (PBMCs) and Stimulation Analysis Via ICS in Baseline and Post-treatment Biopsies, if Clinically Indicated
Evaluate immunologic response of PBMCs (analysis of surface markers, CD3, CD4, CD8, CD19, CD25, CD45, CD56, FoxP3, and degranulation) and stimulation analysis via ICS of interferon gamma (IFNγ) and granzyme B (gzB)
Time frame: Up to 3 years
Total PBMC Counts by Flow Cytometry
Evaluate total PBMC counts by flow cytometry, including lymphocyte subsets (B cells, helper T-cells, cytotoxic T-cells, natural killer (NK) cells and T-reg)
Time frame: Up to 3 years
Tumor Antigen Expression
Evaluation of pre-treatment tumor tissue for antigen expression
Time frame: At screening
Tumor Infiltrating Lymphocytes (TILs)
Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs
Time frame: Up to 3 years
T Cell Receptor Sequencing of Peripheral Blood T Cells Before and During Treatment
Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs, T cell receptor sequencing of peripheral blood T cells before and during the course of treatment.
Time frame: Up to 2 years
Safety of the Combination of the HS-410 and BCG
Phase 2 only Evaluate the safety of the combination of vesigenurtacel-L and BCG
Time frame: Up to 1 year
Safety of the High Dose HS-410 Monotherapy
Phase 2 only Evaluate the safety of high dose vesigenurtacel-L monotherapy
Time frame: Up to 3 years.
| Milestone | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|---|
| Started | 10 | 26 | 26 | 26 | 16 |
| Completed | 10 | 17 | 16 | 23 | 3 |
| Not completed | 0 | 9 | 10 | 3 | 13 |
To evaluate the safety and tolerability of vesigenurtacel-L
| Participants | Phase I: HS-410 Low Dose |
|---|---|
| Gastrointestinal Disorders | 3 |
| General Disorders & Administration Site Conditions | 5 |
| Musculoskeletal & Connective Tissue Disorders | 1 |
Arm 1, 2, 3: 1-year DFS in patients with NMIBC treated with BCG in combination with blinded study product (one of two doses of vesigenurtacel-L or placebo) Arm 4: 1-year DFS in patients with NMIBC treat1fv 9 with high dose vesigenurtacel-L monotherapy One-year disease-free survival will be defined as the proportion of patients who are free from recurrent disease, progressive disease, and alive one year after the date of randomization/treatment assignment
| Participants | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|
| Phase 2: 1-year Disease-Free Survival | 7 | 9 | 6 | 12 |
Evaluate the proportion of patients with recurrence at 3, 6, 12, 18, and 24 months
| participants | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|
| 3 months | 22 | 19 | 23 | 14 |
| 6 months | 19 | 19 | 22 | 9 |
| 12 months | 18 | 17 | 21 | 4 |
| 18 months | 18 | 16 | 15 | 2 |
| 24 months | 14 | 14 | 12 | 1 |
Evaluate the proportion of patients with progressive disease at 3, 6, 12, 18, and 24
| participants | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|
| 3 Months | 1 | 1 | 0 | 0 |
| 6 Months | 2 | 3 | 0 | 3 |
| 12 Months | 2 | 3 | 1 | 3 |
| 18 Months | 2 | 3 | 2 | 4 |
| 24 Months | 2 | 3 | 2 | 4 |
Evaluate Disease Free Survival at 3, 6, 18 and 24 months
| participants | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|
| 3 months | 22 | 19 | 23 | 14 |
| 6 months | 19 | 19 | 22 | 9 |
| 12 months | 18 | 17 | 21 | 4 |
| 18 months | 17 | 16 | 15 | 2 |
| 24 months | 13 | 14 | 12 | 1 |
Evaluate overall Disease Free Survival
| participants | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|
| Overall Disease-free Survival | 18 | 17 | 18 | 3 |
Evaluate overall survival (OS)
| participants | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|
| Overall Survival, Expressed as the Number of Participants Alive | 26 | 26 | 26 | 16 |
| participants | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG |
|---|---|---|---|
| 12 Month | 8 | 6 | 10 |
| 24 Months | 8 | 7 | 11 |
Evaluate the proportion of patients undergoing cystectomy by 12 and 24 months from randomization
| participants | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|
| 12 Months | 0 | 0 | 0 | 1 |
| 24 Months | 1 | 0 | 0 | 1 |
Evaluate the proportion of patients with immunologic response of peripheral blood mononuclear cells (PBMCs) via intracellular cytokine staining (ICS) by flow cytometry and/or ELISPOT on CD8+ cells following vesigenurtacel-L vaccination
No measurements were reported for this outcome.
Evaluate immunologic response of PBMCs (analysis of surface markers, CD3, CD4, CD8, CD19, CD25, CD45, CD56, FoxP3, and degranulation) and stimulation analysis via ICS of interferon gamma (IFNγ) and granzyme B (gzB)
No measurements were reported for this outcome.
Evaluate total PBMC counts by flow cytometry, including lymphocyte subsets (B cells, helper T-cells, cytotoxic T-cells, natural killer (NK) cells and T-reg)
No measurements were reported for this outcome.
Evaluation of pre-treatment tumor tissue for antigen expression
No measurements were reported for this outcome.
Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs
No measurements were reported for this outcome.
Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs, T cell receptor sequencing of peripheral blood T cells before and during the course of treatment.
No measurements were reported for this outcome.
Phase 2 only Evaluate the safety of the combination of vesigenurtacel-L and BCG
No measurements were reported for this outcome.
Phase 2 only Evaluate the safety of high dose vesigenurtacel-L monotherapy
No measurements were reported for this outcome.
Collected over AEs were defined as all reported events with a start date on or after Study Day 1. All AEs were collected through 30 days post last dose, up to 3 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I: HS-410 Low Dose | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Phase II: HS-410 Low-Dose Plus BCG | 0/26 (0%) | 8/26 (30.8%) | 24/26 (92.3%) |
| Phase II: High-Dose HS-410 Plus BCG | 0/26 (0%) | 4/26 (15.4%) | 19/26 (73.1%) |
| Phase II: Placebo Plus BCG | 0/26 (0%) | 1/26 (3.8%) | 20/26 (76.9%) |
| Phase II: High-Dose HS-410 | 0/16 (0%) | 2/16 (12.5%) | 9/16 (56.3%) |
| Event | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|---|
| Urinary Tract InfectionInfections and infestations | 0/10 | 2/26 | 0/26 | 0/26 | 0/16 |
| Urinary RetentionRenal and urinary disorders | 0/10 | 0/26 | 0/26 | 0/26 | 1/16 |
| Bladder PerforationRenal and urinary disorders | 0/10 | 0/26 | 0/26 | 0/26 | 1/16 |
| CystoprostatectomyRenal and urinary disorders | 0/10 | 1/26 | 0/26 | 0/26 | 0/16 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/10 | 1/26 | 0/26 | 0/26 | 0/16 |
| Prostate CancerMusculoskeletal and connective tissue disorders | 0/10 | 1/26 | 0/26 | 1/26 | 0/16 |
| PyrexiaGeneral disorders | 0/10 | 1/26 | 0/26 | 0/26 | 0/16 |
| AneurysmVascular disorders | 0/10 | 1/26 | 0/26 | 0/26 | 0/16 |
| Transient Ischaemic AttackNervous system disorders | 0/10 | 1/26 | 0/26 | 0/26 | 0/16 |
| Mental Status ChangesPsychiatric disorders | 0/10 | 1/26 | 0/26 | 0/26 | 0/16 |
| Event | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 |
|---|---|---|---|---|---|
| Injection Site PainGeneral disorders | 4/10 | 0/26 | 0/26 | 0/26 | 0/16 |
| FatigueGeneral disorders | 0/10 | 10/26 | 6/26 | 4/26 | 3/16 |
| DysuriaRenal and urinary disorders | 0/10 | 3/26 | 6/26 | 9/26 | 0/16 |
| Urinary Tract InfectionInfections and infestations | 1/10 | 8/26 | 3/26 | 6/26 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 3/10 | 0/26 | 4/26 | 0/26 | 0/16 |
| NauseaGastrointestinal disorders | 0/10 | 1/26 | 6/26 | 1/26 | 0/16 |
| HaematuriaRenal and urinary disorders | 0/10 | 6/26 | 5/26 | 3/26 | 0/16 |
| VomitingGastrointestinal disorders | 0/10 | 2/26 | 5/26 | 0/26 | 0/16 |
| ChillsGeneral disorders | 0/10 | 5/26 | 4/26 | 3/26 | 0/16 |
| PyrexiaGeneral disorders | 0/10 | 5/26 | 3/26 | 3/26 | 0/16 |
| Age, Categorical(Participants) | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 7 | 12 | 6 | 1 | 27 |
| >=65 years | 9 | 19 | 14 | 20 | 15 | 77 |
| Age, Continuous(years) | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 | Total |
|---|---|---|---|---|---|---|
| Mean | 73.2 ± 7.495 | 70.5 ± 11.176 | 68.58 ± 11.518 | 70.58 ± 9.047 | 72.50 ± 9.784 | 70.60 ± 10.172 |
| Sex: Female, Male(Participants) | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 3 | 5 | 6 | 3 | 18 |
| Male | 9 | 23 | 21 | 20 | 13 | 86 |
| Ethnicity (NIH/OMB)(Participants) | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 2 | 2 | 0 | 5 |
| Not Hispanic or Latino | 10 | 25 | 24 | 24 | 16 | 99 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 2 | 0 | 2 |
| White | 10 | 26 | 25 | 23 | 16 | 100 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Phase I: HS-410 Low Dose | Phase II: HS-410 Low-Dose Plus BCG | Phase II: High-Dose HS-410 Plus BCG | Phase II: Placebo Plus BCG | Phase II: High-Dose HS-410 | Total |
|---|---|---|---|---|---|---|
| United States | 10 | 26 | 26 | 26 | 16 | 104 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Dec 2013, a primary completion of Dec 2017 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2020, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BCG Vaccine
Heat Biologics